Abstract
- Obesity and its associated morbidities and mortalities are the effects of imbalance between energy intake and expenditure. The healthcare burden for the treatment of obesity is significantly high, due to increased risk of secondary chronic diseases such as hypertension and associated co-morbidities such as diabetes and cardiovascular disease. Lack of physical activity, high fat diets and sedentary life styles are major factors contributing to obesity. However, genetic predisposition and ethnicity are increasingly found to cause obesity. Till date, approved therapeutics have addressed excess energy intake by acting on central neural circuits that regulate feeding or on peripheral mechanisms to reduce nutrient absorption from the gut. These approaches have met with moderate success; and recently with safety concerns, leaving an unmet medical need for effective and safe pharmacotherapy for obesity thereby posing a significant challenge to pharmaceutical industry. Potential antiobesity drugs, which are being investigated by different companies, can be classified in 4 broad categories: 1) Agents that primarily decrease appetite through central action; 2) Agents that primarily increase metabolic rate or affect metabolism through peripheral action; 3) Agents that act on gastrointestinal tract; and 4) Agents that not only affect obesity but also overall Metabolic Syndrome. The current review will deal mainly with different molecules, which are under development for the above-mentioned targets and also their potential benefits and disadvantages.
Keywords: Sibutramine, endocannabinoids, pharmacophore model, CB1 antagonists, MC4 receptor, POMC
Current Medicinal Chemistry
Title: Antiobesity Therapy: Emerging Drugs and Targets
Volume: 13 Issue: 12
Author(s): Saibal K. Das and Ranjan Chakrabarti
Affiliation:
Keywords: Sibutramine, endocannabinoids, pharmacophore model, CB1 antagonists, MC4 receptor, POMC
Abstract: - Obesity and its associated morbidities and mortalities are the effects of imbalance between energy intake and expenditure. The healthcare burden for the treatment of obesity is significantly high, due to increased risk of secondary chronic diseases such as hypertension and associated co-morbidities such as diabetes and cardiovascular disease. Lack of physical activity, high fat diets and sedentary life styles are major factors contributing to obesity. However, genetic predisposition and ethnicity are increasingly found to cause obesity. Till date, approved therapeutics have addressed excess energy intake by acting on central neural circuits that regulate feeding or on peripheral mechanisms to reduce nutrient absorption from the gut. These approaches have met with moderate success; and recently with safety concerns, leaving an unmet medical need for effective and safe pharmacotherapy for obesity thereby posing a significant challenge to pharmaceutical industry. Potential antiobesity drugs, which are being investigated by different companies, can be classified in 4 broad categories: 1) Agents that primarily decrease appetite through central action; 2) Agents that primarily increase metabolic rate or affect metabolism through peripheral action; 3) Agents that act on gastrointestinal tract; and 4) Agents that not only affect obesity but also overall Metabolic Syndrome. The current review will deal mainly with different molecules, which are under development for the above-mentioned targets and also their potential benefits and disadvantages.
Export Options
About this article
Cite this article as:
Das K. Saibal and Chakrabarti Ranjan, Antiobesity Therapy: Emerging Drugs and Targets, Current Medicinal Chemistry 2006; 13 (12) . https://dx.doi.org/10.2174/092986706776872880
DOI https://dx.doi.org/10.2174/092986706776872880 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biogenic Peptides and Their Potential Use
Current Pharmaceutical Design Insight on the Body Fat Lowering Effect of 3,5-Diiodo-L-Thyronine
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Minoxidil Use in Dermatology, Side Effects and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Prevalence of Cardiovascular and Metabolic Events in Patients Prescribed Clozapine: A Retrospective Observational, Clinical Cohort Study
Current Drug Safety Role of Micronutrients on Subclinical Atherosclerosis Micronutrients in Subclinical Atherosclerosis
Current Pharmaceutical Design Pharmacological and Lifestyle Factors Modulating Serum Paraoxonase-1 Activity
Mini-Reviews in Medicinal Chemistry Pharmacokinetics and Acute Toxicity of a Histone Deacetylase Inhibitor, Scriptaid, and its Neuroprotective Effects in Mice After Intracranial Hemorrhage
CNS & Neurological Disorders - Drug Targets Nutrigenomics and Its Approaches for Control of Chronic Diseases
Current Biotechnology New Patents on Topical Anesthetics
Recent Patents on Inflammation & Allergy Drug Discovery Quick-Release Bromocriptine for Treatment of Type 2 Diabetes
Current Drug Delivery Cardioprotective Potential of Iron Chelators and Prochelators
Current Medicinal Chemistry Cardiovascular Complications of Sleep Disorders: A Better Night’s Sleep for a Healthier Heart / From Bench to Bedside
Current Vascular Pharmacology Cyclooxygenase-2 Inhibitors as a Therapeutic Target in Inflammatory Diseases
Current Medicinal Chemistry EDHF and Gap Junctions: Important Regulators of Vascular Tone Within the Microcirculation
Current Pharmaceutical Biotechnology The Therapeutic Potential of Angiotensin-(1-7) as a Novel Renin- Angiotensin System Mediator
Mini-Reviews in Medicinal Chemistry Circulating Endothelial Progenitor Cells Characterization, Function and Relationship with Cardiovascular Risk Factors
Current Pharmaceutical Design Gene Therapy Targeting Inflammation in Atherosclerosis
Current Pharmaceutical Design Review: Metabolism of Immunosuppressant Drugs
Current Drug Metabolism Protein Kinases as Drug Targets in Human and Animal Diseases
Current Enzyme Inhibition Obesity and Pregnancy
Current Women`s Health Reviews